To conquer solid tumors as the enterprise mission, to develop cell drugs (CAR-T, CAR-NK, TIL, etc.), antibody drugs, gene drugs, etc.

Based on the Songshan Lake (Celconta) comprehensive cell Bank, based on Dongguan and facing the whole country, it focuses on the storage of neonatal umbilical cord / placental stem cells and adult immune cells.

Based on the Songshan Lake (Celconta) Regional Cell Preparation Center, it is committed to the research of stem cells and regenerative medicine and the modernization, standardization and large-scale production of clinical-grad cell products.

The company uses a know-how-based R&D strategy to find new treatment targets, starting with motor neurone disease and gradually expanding to gene therapy and translational research for other neurodegenerative diseases. It plans to apply for 2-4 patents or orphan drugs, and transform new drug research and development into clinical trials and clinical applications.